Enveda Biosciences is a Boulder-based clinical-stage biotechnology company focused on turning the chemistry of the natural world into first-in-class oral small-molecule medicines. Its platform organizes plant-derived molecules into a searchable library, uses machine learning to resolve structures from analytical data, and applies automated high-throughput testing to connect those structures with disease biology across inflammation, metabolic, and gastrointestinal programs.
The company reports a wholly owned pipeline spanning discovery through clinical trials, led by candidates for atopic dermatitis, asthma, weight-loss maintenance, and inflammatory bowel disease. Backed by substantial venture financing and governed as a venture-backed enterprise, Enveda positions its chemical-sequencing approach as a faster and broader route to differentiated therapies than conventional screening.
First-in-class gut-preferred once-daily oral small-molecule candidate with a novel TL1A+ pathway inhibitor mechanism in Phase 1 for inflammatory bowel disease.
AI-enabled natural-product drug discovery platform organizing plant chemistry into a searchable library with machine-learning translation and automated screening.
